Goldman Sachs predicts that increased use of weight-loss drugs like Ozempic could boost US GDP by 1-3% by 2030 due to more efficient workers and fewer sick days.
Goldman Sachs forecasts that increased use of weight-loss drugs, particularly GLP-1 agonists like Ozempic, could boost US GDP by 1-3% by 2030 due to more efficient workers and fewer sick days due to obesity-related illnesses. With a potential 10-70 million consumers using these drugs by 2028, the market could reach $100 billion annually, with Novo Nordisk and Eli Lilly as leading producers. The drugs could contribute to a significant spillover effect on the US economy as obese individuals become more productive in the workforce.
February 22, 2024
11 Articles